PT901487E - 4(3h)-quinazolinonas 2,3,6-trissubstituidas - Google Patents
4(3h)-quinazolinonas 2,3,6-trissubstituidasInfo
- Publication number
- PT901487E PT901487E PT97901749T PT97901749T PT901487E PT 901487 E PT901487 E PT 901487E PT 97901749 T PT97901749 T PT 97901749T PT 97901749 T PT97901749 T PT 97901749T PT 901487 E PT901487 E PT 901487E
- Authority
- PT
- Portugal
- Prior art keywords
- trissubstituides
- quinazolinones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1773896P | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT901487E true PT901487E (pt) | 2003-08-29 |
Family
ID=21784266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97901749T PT901487E (pt) | 1996-05-15 | 1997-02-17 | 4(3h)-quinazolinonas 2,3,6-trissubstituidas |
Country Status (39)
Country | Link |
---|---|
US (1) | US6303615B1 (pt) |
EP (1) | EP0901487B9 (pt) |
JP (1) | JP3241388B2 (pt) |
KR (1) | KR100375155B1 (pt) |
CN (2) | CN1103772C (pt) |
AP (1) | AP1148A (pt) |
AR (1) | AR007118A1 (pt) |
AT (1) | ATE242232T1 (pt) |
AU (1) | AU730503B2 (pt) |
BG (1) | BG102999A (pt) |
BR (1) | BR9709085A (pt) |
CA (1) | CA2252907C (pt) |
CZ (1) | CZ295565B6 (pt) |
DE (1) | DE69722613T2 (pt) |
DK (1) | DK0901487T3 (pt) |
DZ (1) | DZ2237A1 (pt) |
EA (1) | EA002905B1 (pt) |
ES (1) | ES2198546T3 (pt) |
GT (1) | GT199700049A (pt) |
HK (1) | HK1019607A1 (pt) |
HN (1) | HN1997000052A (pt) |
HR (1) | HRP970261B1 (pt) |
HU (1) | HUP9902148A3 (pt) |
ID (1) | ID17149A (pt) |
IL (1) | IL126589A (pt) |
IS (1) | IS4881A (pt) |
MA (1) | MA26430A1 (pt) |
NO (1) | NO985293L (pt) |
OA (1) | OA10918A (pt) |
PL (1) | PL330042A1 (pt) |
PT (1) | PT901487E (pt) |
SI (1) | SI0901487T1 (pt) |
SK (1) | SK284108B6 (pt) |
TN (1) | TNSN97087A1 (pt) |
TR (1) | TR199802296T2 (pt) |
TW (1) | TW539675B (pt) |
WO (1) | WO1997043276A1 (pt) |
YU (1) | YU19197A (pt) |
ZA (1) | ZA974156B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL130900A0 (en) * | 1997-02-28 | 2001-01-28 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts |
PL335307A1 (en) | 1997-02-28 | 2000-04-10 | Pfizer Prod Inc | Atropoisomers of 3-heteroaryl-4(3h)-quinazolynes for treating neurodegenerative and traumatic states of central nervous system |
US6060479A (en) * | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
EP0900567A3 (en) * | 1997-09-05 | 2001-05-02 | Pfizer Products Inc. | Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy |
JPH11279158A (ja) * | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―4―オン誘導体の製造方法 |
DE60027546T2 (de) | 1999-02-15 | 2007-04-26 | Eisai Co., Ltd. | Heterodiazinon-derivate |
US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP1300396B1 (en) | 2000-06-12 | 2009-01-14 | Eisai R&D Management Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
US7053216B2 (en) | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
JP2006501201A (ja) * | 2002-07-23 | 2006-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
CN101355946B (zh) * | 2005-11-04 | 2013-05-08 | 海德拉生物科学公司 | 调节trpv3功能的化合物 |
KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체 |
WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
CN101952272B (zh) * | 2007-09-26 | 2014-08-27 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
AU2009209811B2 (en) | 2008-01-30 | 2011-07-21 | Shin Poong Pharmaceutical Co., Ltd. | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
ES2674719T3 (es) | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
EP2411391A1 (en) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
US9216177B2 (en) | 2011-02-28 | 2015-12-22 | Drexel University | Small molecular inhibitors of RAD51 recombinase and methods thereof |
AR090253A1 (es) | 2012-03-05 | 2014-10-29 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
MX2016008259A (es) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. |
SG11201609877XA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
CN113226286A (zh) | 2018-12-14 | 2021-08-06 | 卫材R&D管理有限公司 | 1,2-二氢吡啶化合物的水基药物制剂 |
JP2023512664A (ja) | 2020-01-29 | 2023-03-28 | カマリ ファーマ リミテッド | 皮膚障害の治療に使用するための化合物及び組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1195321B (de) * | 1962-03-16 | 1965-06-24 | Troponwerke Dinklage & Co | Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten |
DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
GB1298603A (en) | 1970-04-06 | 1972-12-06 | Karamchand Premchand Private | Quinazolinone derivatives |
AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
GB9022785D0 (en) | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
US5284957A (en) | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
DE69401583T2 (de) | 1993-05-06 | 1997-06-12 | Novonordisk As | [1,2,4-TRIAZOLO[4,3-a]CHINOXALINVERBINDUNGEN DEREN HERSTELLUNG UND VERWENDUNG |
GB9400680D0 (en) | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
IL130900A0 (en) | 1997-02-28 | 2001-01-28 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts |
-
1997
- 1997-02-17 ES ES97901749T patent/ES2198546T3/es not_active Expired - Lifetime
- 1997-02-17 HU HU9902148A patent/HUP9902148A3/hu unknown
- 1997-02-17 CZ CZ19983526A patent/CZ295565B6/cs not_active IP Right Cessation
- 1997-02-17 US US09/180,732 patent/US6303615B1/en not_active Expired - Fee Related
- 1997-02-17 PL PL97330042A patent/PL330042A1/xx unknown
- 1997-02-17 KR KR10-1998-0709205A patent/KR100375155B1/ko not_active IP Right Cessation
- 1997-02-17 EA EA199800923A patent/EA002905B1/ru not_active IP Right Cessation
- 1997-02-17 PT PT97901749T patent/PT901487E/pt unknown
- 1997-02-17 DK DK97901749T patent/DK0901487T3/da active
- 1997-02-17 AT AT97901749T patent/ATE242232T1/de not_active IP Right Cessation
- 1997-02-17 JP JP54068297A patent/JP3241388B2/ja not_active Expired - Fee Related
- 1997-02-17 CN CN97194654A patent/CN1103772C/zh not_active Expired - Fee Related
- 1997-02-17 EP EP97901749A patent/EP0901487B9/en not_active Expired - Lifetime
- 1997-02-17 BR BR9709085A patent/BR9709085A/pt not_active Application Discontinuation
- 1997-02-17 SI SI9730555T patent/SI0901487T1/xx unknown
- 1997-02-17 AU AU15549/97A patent/AU730503B2/en not_active Ceased
- 1997-02-17 TR TR1998/02296T patent/TR199802296T2/xx unknown
- 1997-02-17 CA CA002252907A patent/CA2252907C/en not_active Expired - Fee Related
- 1997-02-17 SK SK1520-98A patent/SK284108B6/sk unknown
- 1997-02-17 WO PCT/IB1997/000134 patent/WO1997043276A1/en active IP Right Grant
- 1997-02-17 DE DE69722613T patent/DE69722613T2/de not_active Expired - Fee Related
- 1997-04-08 TW TW086104460A patent/TW539675B/zh active
- 1997-04-21 HN HN1997000052A patent/HN1997000052A/es unknown
- 1997-04-29 GT GT199700049A patent/GT199700049A/es unknown
- 1997-05-13 AR ARP970102001A patent/AR007118A1/es not_active Application Discontinuation
- 1997-05-14 DZ DZ970085A patent/DZ2237A1/fr active
- 1997-05-14 YU YU19197A patent/YU19197A/sh unknown
- 1997-05-14 ID IDP971603A patent/ID17149A/id unknown
- 1997-05-14 TN TNTNSN97087A patent/TNSN97087A1/fr unknown
- 1997-05-14 MA MA24613A patent/MA26430A1/fr unknown
- 1997-05-14 ZA ZA974156A patent/ZA974156B/xx unknown
- 1997-05-15 AP APAP/P/1997/001003A patent/AP1148A/en active
- 1997-05-15 HR HR970261A patent/HRP970261B1/xx not_active IP Right Cessation
- 1997-12-17 IL IL12658997A patent/IL126589A/xx not_active IP Right Cessation
-
1998
- 1998-10-27 IS IS4881A patent/IS4881A/is unknown
- 1998-11-06 OA OA9800216A patent/OA10918A/en unknown
- 1998-11-13 NO NO985293A patent/NO985293L/no unknown
- 1998-12-08 BG BG102999A patent/BG102999A/xx active Pending
-
1999
- 1999-10-27 HK HK99104806A patent/HK1019607A1/xx not_active IP Right Cessation
-
2002
- 2002-09-05 CN CN02131946A patent/CN1420114A/zh active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT901487E (pt) | 4(3h)-quinazolinonas 2,3,6-trissubstituidas | |
MA23780A1 (fr) | Quinazolinones 2, 8 disubstitues | |
TR199600265A1 (tr) | Kinazolin türevleri. | |
IS4970A (is) | Setnar 6,6-heteró-bísýklískar afleiður | |
DK0823900T3 (da) | Quinazolinderivater | |
NO2006016I1 (no) | 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat | |
PT993456E (pt) | 4,5-diaril-imidazoles 2-substituidos | |
BR9506532A (pt) | 1,2,3,4,-Tetraidro-5-Nitro-Pirimidinas substituidas | |
NO985335D0 (no) | 2,4-Diaminopyrimidinderivater | |
BR9609884A (pt) | N-aril- 1,2,4-triazolin-5-onas | |
DE69618634D1 (de) | 1,4-benzodioxin-derivate | |
ID26909A (id) | Turunan-turunan 1,3,4-oksadiazolon | |
DK1068200T3 (da) | 2,4,4-trisubstituerede-1,3-dioxolanfungicider | |
ID24047A (id) | Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on | |
FR2716157B1 (fr) | Agencement d'ancrage. | |
DE69815072D1 (de) | Substituierte 2,4-diaminopyrimidine | |
FR2724962B3 (fr) | Tuile d'avant-toit sous-faitiere. | |
BR9610047A (pt) | 1,3,4-oxadiazolin-2-onas | |
IT1283187B1 (it) | "elettrovalvola." | |
IT1274643B (it) | Costruzione rapida "isodomus". | |
ES1038172Y (es) | "caja-contenedor". |